George-
As much as anyone,I would love to know more about the details of what goes on during a trial.
However,Xoma has a track record with the FDA, having to do with
E-5 that was combative,to say the least! In light of that,I am
strongly in favor of the company deciding to be most conservative
in the news it releases about its trials or products. Yes,it would be wonderful to have known what the specific mortality event target
was and what progress was being made toward that number,but,
if in fact the DSMB was specific about not letting this info out to the public or not,the company chose to be silent about all this
and if you are a long term shareholder you have to respect the choice they have made. You might not agree with the choice the company made.
I do! In fact, I believe,in the interest of approval of this compound,that the company should say as little as possible about the appoval process before or after the drug is approved.
|
